Trulieve Cannabis: First NYSE-Listed Cannabis Stock Is A Buy

Impact · against what's priced in

Trulieve is positioned for significant valuation expansion due to the combined impact of NYSE uplisting and the removal of 280E tax burdens. These factors, alongside proven free cash flow and buybacks, provide concrete catalysts for institutional entry and earnings growth.

TRLV+0.90

No priced-in read yet

In context

The transition to Schedule III removes the 280E tax burden, while the NYSE uplisting and $42 million in Q1 2026 free cash flow fundamentally shift the company's liquidity and profitability profile.

Read from the article alone

• cash flow▲29%
• earnings▲27%
• TRLV
• cannabis
• nyse
• schedule iii
• share buyback
• tax relief